54.25
전일 마감가:
$53.55
열려 있는:
$54.15
하루 거래량:
1.31M
Relative Volume:
0.60
시가총액:
$6.91B
수익:
$947.36M
순이익/손실:
$392.47M
주가수익비율:
17.96
EPS:
3.02
순현금흐름:
$392.71M
1주 성능:
-3.25%
1개월 성능:
-8.64%
6개월 성능:
+12.09%
1년 성능:
+5.46%
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
HALO을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
HALO
Halozyme Therapeutics Inc
|
54.25 | 6.91B | 947.36M | 392.47M | 392.71M | 3.02 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-05-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2025-05-13 | 다운그레이드 | Leerink Partners | Market Perform → Underperform |
2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2024-02-29 | 개시 | TD Cowen | Outperform |
2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
2023-07-24 | 개시 | H.C. Wainwright | Buy |
2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2023-03-27 | 재개 | Berenberg | Buy |
2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
2022-12-21 | 재개 | Morgan Stanley | Overweight |
2022-11-28 | 개시 | Wells Fargo | Overweight |
2022-09-09 | 개시 | Morgan Stanley | Overweight |
2022-05-23 | 개시 | SVB Leerink | Outperform |
2021-06-14 | 개시 | Evercore ISI | Outperform |
2021-05-17 | 개시 | SVB Leerink | Outperform |
2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2021-01-21 | 재확인 | The Benchmark Company | Buy |
2020-12-17 | 개시 | Berenberg | Buy |
2020-09-14 | 재개 | JP Morgan | Overweight |
2020-07-01 | 개시 | The Benchmark Company | Buy |
2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
2020-01-08 | 개시 | Goldman | Buy |
2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
2018-10-19 | 재개 | Piper Jaffray | Neutral |
2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
2018-01-24 | 개시 | Goldman | Neutral |
2017-10-16 | 재확인 | Piper Jaffray | Overweight |
2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
2016-11-03 | 개시 | Deutsche Bank | Buy |
2015-12-04 | 개시 | Wells Fargo | Outperform |
2015-11-18 | 개시 | Citigroup | Buy |
2015-09-22 | 개시 | Barclays | Overweight |
2015-06-22 | 재확인 | JP Morgan | Overweight |
2015-03-03 | 재확인 | UBS | Buy |
2015-02-18 | 재확인 | MLV & Co | Buy |
2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Merck gains U.S. patent office support in Keytruda dispute - MSN
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility - mx.advfn.com
Why Is Halozyme Therapeutics (HALO) Down 23.2% Since Last Earnings Report? - Yahoo Finance
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years - Benzinga
Merck (MRK) Gains Edge in Keytruda Patent Dispute - GuruFocus
Merck dispute with Halozyme over Keytruda injection to get another USPTO look - Seeking Alpha
Meridian Growth Fund Trimmed Halozyme Therapeutics (HALO) for the Valuation Discipline - Insider Monkey
PGR institution likely weakens Halozyme bull case scenario, says Wells Fargo - Yahoo Finance
Merck granted review of Halozyme patent claims by PTAB - Yahoo Finance
Zacks.com featured highlights Sterling Infrastructure, BJ's Wholesale, Molina Healthcare and Halozyme - Yahoo Finance
Halozyme (HALO) Faces Patent Challenge as USPTO Institutes Revie - GuruFocus
Halozyme (HALO) Faces Patent Challenges Affecting Stock Outlook | HALO Stock News - GuruFocus
Here’s Why Halozyme Therapeutics (HALO) Rebounded in Q1 - Insider Monkey
(HALO) Investment Report - news.stocktradersdaily.com
H.C. Wainwright Reiterates Buy on Halozyme (HALO), Maintains Price Target - MSN
Halozyme to Participate at Upcoming Investor Conferences - Kilgore News Herald
Halozyme Therapeutics (NASDAQ:HALO) Receives “Buy” Rating from HC Wainwright - Defense World
Halozyme Therapeutics (HALO): HC Wainwright & Co. Reiterates Buy Rating | HALO Stock News - GuruFocus
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications - Longview News-Journal
Halozyme stock holds Buy rating, $72 target from H.C. Wainwright By Investing.com - Investing.com UK
Halozyme to Participate at Upcoming Investor Conferences | HALO Stock News - GuruFocus
Halozyme CEO Sets Two Major Healthcare Conference Appearances: Goldman Sachs and Benchmark - Stock Titan
3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO) - sharewise
Bristol-Myers wins EU nod for Opdivo injectable developed with Halozyme - MSN
Implied Volatility Surging for Halozyme Therapeutics Stock Options - The Globe and Mail
Bristol Myers Squibb, Halozyme Get EC Approval for Subcutaneous Formulation of Opdivo - marketscreener.com
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock - Yahoo Finance
Halozyme Says Bristol-Myers Squibb Gets EC Approval For Opdivo SC Developed With Halozyme's ENHANZE - Nasdaq
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications | HALO Stock News - GuruFocus
High Growth Tech Stocks To Watch In The US May 2025 - Yahoo Finance
New Strong Buy Stocks for May 28th - The Globe and Mail
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Recommendation of “Hold” by Brokerages - Defense World
J&J, Halozyme cut at Leerink on price control risk for combo products - MSN
Halozyme Therapeutics (NASDAQ:HALO) Cut to “Strong Sell” at Leerink Partnrs - Defense World
Halozyme downgraded at Morgan Stanley on price control risk - MSN
Morgan Stanley Downgrades Halozyme Therapeutics (BIT:1HALO) - Nasdaq
Zacks.com featured highlights Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme - Yahoo Finance
Morgan Stanley Downgrades Halozyme Therapeutics (LSE:0J2O) - Nasdaq
Leerink Partners Downgrades Halozyme Therapeutics (LSE:0J2O) - Nasdaq
Leerink Partners Downgrades Halozyme Therapeutics (NASDAQ:HALO) to Underperform - Defense World
Halozyme (HALO) Downgraded by Morgan Stanley Amid Pricing Concer - GuruFocus
Leerink Partners Downgrades Halozyme Therapeutics (BMV:HALO) - Nasdaq
Halozyme Therapeutics (HALO) Downgraded by Morgan Stanley | HALO Stock News - GuruFocus
Halozyme, J&J slide as analyst cuts rating on CMS draft guidance - Yahoo Finance
Halozyme (HALO) Downgraded Amid Medicare Price Negotiation Conce - GuruFocus
Halozyme stock downgraded at Morgan Stanley (HALO:NASDAQ) - Seeking Alpha
Halozyme Therapeutics downgraded by Morgan Stanley with a new price target - Quantisnow
Why Halozyme Therapeutics, Inc. (HALO) Declined on Tuesday - Yahoo Finance
Halozyme stock holds $78 target despite Medicare concerns By Investing.com - Investing.com Canada
Halozyme (HALO) Downgraded by Morgan Stanley Amid Pricing Concerns | HALO Stock News - GuruFocus
Halozyme stock holds $78 target despite Medicare concerns - Investing.com
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):